Another fledgling biopharma company is planning to go public.
And Viking Global Investors is potentially the biggest beneficiary of the offering.
RayzeBio on Friday filed plans for an initial public offering. It did not disclose the number of shares it plans to offer or the price range it is seeking.
The
